Stocks · News reference
Xeris Biopharma Holdings (NASDAQ:XERS) raises FY2026 sales outlook from $380.000 million-$390.000 million to $385.000 million-$390.000 million vs $385.229 million estimate.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $9 to $12.
Read original at benzingaFiled: 2026-08-06 AccNo: 0001867096-26-000063 Size: 334 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar